Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 14
    records per page




    The impact of COVID-19 in diabetic kidney disease MESHD kidney disease and chronic HP chronic kidney disease MESHD: A population-based study

    Authors: Juan Alonso Leon-Abarca; Roha Saeed Memon; Bahar Rehan; Maimoona Iftikhar; Antara Chatterjee; Andrés Gonzalez-Guerra; Emilio Camafeita; Mariya Lytvyn; María Isabel Guillén; David Sanz-Rosa; Daniel Martín-Pérez; Cristina Sanchez-Ramos; Ricardo Garcia; Juan Antonio Bernal; Sijia Tao; Tristan R Horton; Elizabeth N Beagle; Ernestine A Mahar; Michelle YH Lee; Joyce Cohen; Sherrie Jean; Jennifer S Wood; Fawn Connor-Stroud; Rachelle L Stammen; Olivia M Delmas; Shelly Wang; Kimberly A Cooney; Michael N Sayegh; Lanfang Wang; Daniela Weiskopf; Peter D Filev; Jesse Waggoner; Anne Piantadosi; Sudhir P Kasturi; Hilmi Al-Shakhshir; Susan P Ribeiro; Rafick P Sekaly; Rebecca D Levit; Jacob D Estes; Thomas H Vanderford; Raymond F Schinazi; Steven E Bosinger; Mirko Paiardini

    doi:10.1101/2020.09.12.20193235 Date: 2020-09-16 Source: medRxiv

    Background: The spectrum of pre-existing renal disease MESHD is known as a risk factor for severe COVID-19 outcomes. However, little is known about the impact of COVID-19 on patients with diabetic nephropathy MESHD nephropathy HP in comparison to patients with chronic kidney disease HP chronic kidney disease MESHD. Methods: We used the Mexican Open Registry of COVID-19 patients 11 to analyze anonymized records of those who had symptoms related to COVID-19 to analyze the rates of SARS-CoV-2 infection MESHD, development of COVID-19 pneumonia HP pneumonia MESHD, admission, intubation, Intensive Care Unit admission and mortality. Robust Poisson regression was used to relate sex and age TRANS to each of the six outcomes and find adjusted prevalences SERO and adjusted prevalence SERO ratios. Also, binomial regression models were performed for those outcomes that had significant results to generate probability plots to perform a fine analysis of the results obtained along age TRANS as a continuous variable. Results: The adjusted prevalence SERO analysis revealed that that there was a a 87.9% excess probability of developing COVID-19 pneumonia HP pneumonia MESHD in patients with diabetic nephropathy MESHD nephropathy HP, a 5% excess probability of being admitted, a 101.7% excess probability of intubation and a 20.8% excess probability of a fatal outcome due to COVID-19 pneumonia HP pneumonia MESHD in comparison to CKD patients (p<0.01). Conclusions: Patients with diabetic nephropathy MESHD nephropathy HP had nearly a twofold rate of COVID-19 pneumonia HP pneumonia MESHD, a higher probability of admission, a twofold probability of intubation and a higher chance of death once admitted compared to patients with chronic kidney disease HP chronic kidney disease MESHD alone. Also, both diseases had higher COVID-19 pneumonia HP pneumonia MESHD rates, intubation rates and case-fatality rates compared to the overall population. Keywords: COVID-19, SARS-CoV-2, Chronic Kidney Disease MESHD Chronic Kidney Disease HP, diabetic nephropathy MESHD nephropathy HP

    UK prevalence SERO of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence SERO study using electronic health records

    Authors: Jemma L Walker; Daniel J Grint; Helen Strongman; Rosalind M Eggo; Maria Peppa; Caroline Minassian; Kathryn E Mansfield; Christopher T. Rentsch; Ian J Douglas; Rohini Mathur; Angel Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald

    doi:10.1101/2020.08.24.20179192 Date: 2020-08-26 Source: medRxiv

    Background This study aimed to describe the population at risk of severe COVID-19 due to underlying health conditions across the United Kingdom in 2019. Methods We used anonymised electronic health records from the Clinical Practice Research Datalink GOLD to describe the point prevalence SERO on 5 March 2019 of the at-risk population following national guidance. Prevalence SERO for any risk condition and for each individual condition is given overall and stratified by age TRANS and region. We repeated the analysis on 5 March 2014 for full regional representation and to describe prevalence SERO of underlying health conditions in pregnancy. We additionally described the population of cancer MESHD survivors, and assessed the value of linked secondary care records for ascertaining COVID-19 at-risk status. Findings On 5 March 2019, 24.4% of the UK population were at risk due to a record of at least one underlying health condition, including 8.3% of school- aged TRANS children TRANS, 19.6% of working- aged TRANS adults TRANS, and 66.2% of individuals aged TRANS 70 years or more. 7.1% of the population had multimorbidity. The size of the at-risk population was stable over time comparing 2014 to 2019, despite increases in chronic liver disease MESHD and diabetes MESHD and decreases in chronic kidney disease HP chronic kidney disease MESHD and current asthma HP asthma MESHD. Separately, 1.6% of the population had a new diagnosis of cancer MESHD in the past five years. Interpretation The population at risk of severe COVID-19 ( aged TRANS [≥]70 years, or with an underlying health condition) comprises 18.5 million individuals in the UK, including a considerable proportion of school- aged TRANS and working- aged TRANS individuals.

    Disparities in COVID-19 Hospitalizations and Mortality among Black and Hispanic Patients: Cross-Sectional Analysis from the Greater Houston Metropolitan Area

    Authors: Alan Pan; Osman Khan; Jennifer Meeks; Marc Boom; Faisal Masud; Julia Andrieni; Robert Phillips; Yordanos Tiruneh; Bita Kash; Farhaan Vahidy; Bolin Cheng; Feng Qiu; Pengcheng Yu; Wenting Zhou; Lei Cao; Shengli Bi; Guizhen Wu; George Fu Gao; Jerry Zheng; Dave Osthus; Michael Lingzhi Li; Elizabeth C Lee; Ugur Koyluoglu; Pinar Keskinocak; Youyang Gu; Quanquan Gu; Glover E George; Guido España; Sabrina Corsetti; Jagpreet Chhatwal; Sean Cavany; Hannah Biegel; Michal Ben-Nun; Jo Walker; Rachel Slayton; Velma Lopez; Matthew Biggerstaff; Michael A Johansson; Nicholas G Reich; - COVID-19 Forecast Hub Consortium

    doi:10.1101/2020.08.19.20177956 Date: 2020-08-22 Source: medRxiv

    Disparate racial and ethnic burdens of the Coronavirus Disease MESHD 2019 (COVID-19) pandemic may be attributable to higher susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 MESHD (SARS-CoV-2) or to factors such as differences in hospitalization and care provision. In our cross-sectional analysis of lab-confirmed COVID-19 cases from a tertiary, eight-hospital healthcare system (Houston Methodist) across greater Houston, multivariable logistic regression models were fitted to evaluate the odds of hospitalization and mortality for non-Hispanic Blacks (NHBs) vs. non-Hispanic Whites (NHWs) and Hispanics vs. non-Hispanics. Between March 3rd and July 18th, 2020, 70,496 individuals were tested for SARS-CoV-2; 12,084 (17.1%) tested positive, of whom 3,536 (29.3%) were hospitalized. Among positive cases, NHBs and Hispanics were significantly younger than NHWs and Hispanics, respectively (mean age TRANS NHBs vs. NHWs: 46.0 vs. 51.7 year and Hispanic vs. non-Hispanic: 44.0 vs. 48.7 years). Despite younger age TRANS, NHBs (vs. NHWs) had a higher prevalence SERO of diabetes MESHD (25.2%), hypertension HP hypertension MESHD (47.7%), and chronic kidney disease HP chronic kidney disease MESHD (5.0%). Both minority groups resided in lower median income and higher population density areas. In fully adjusted models, NHBs and Hispanics had higher likelihoods of hospitalization, aOR (CI): 1.42 (1.24-1.63) and 1.61 (1.46-1.78), respectively. No differences were observed in intensive care unit (ICU) utilization or treatment parameters. Models adjusted for demographics, vital signs, laboratory parameters, hospital complications, and ICU admission demonstrated non-significantly lower likelihoods of in-hospital mortality among NHBs and Hispanics, aOR (CI): 0.65 (0.40-1.03) and 0.89 (0.59-1.31), respectively. Our data did not demonstrate racial and ethnic differences in care provision and hospital outcomes. Higher susceptibility of racial and ethnic minorities to SARS-CoV-2 and subsequent hospitalization may be driven primarily by social determinants.

    Diabetic MESHD Patients with Comorbidities had Worse Outcomes When Suffered with COVID-19 and Acarbose might have Protective Effects

    Authors: Weihua Hu, MD; Shunkui Luo; Zhanjin Lu, MD; Chang Li; Qijian Chen; Yameng Fan; Zaishu Chen; Longlong Wu; Jianfang Ye; Shiyan Chen; Junlu Tong; Lingling Wang; Jin Mei; Hongyun Lu

    doi:10.21203/rs.3.rs-57456/v1 Date: 2020-08-11 Source: ResearchSquare

    Background: Previous studies showed that diabetes MESHD was a common comorbidity of COVID-19, but the effects of diabetes MESHD or anti- diabetic MESHD drugs on the mortality of COVID-19 have not been well described. To investigate the outcome of different status (with or without comorbidity) and anti- diabetic MESHD medication before admission of diabetic MESHD patients after SARS-CoV-2 infected MESHD, we collected clinical data of COVID-19 patients from Hubei Province and compared between diabetes MESHD and non-diabetes MESHD.Methods: In this multicenter and retrospective study, we enrolled 1,422 cases of consecutive hospitalized patients from January 21, 2020 to March 25, 2020 at six hospitals in Hubei Province, China. The primary endpoint was in-hospital mortality.Results: Diabetes MESHD patients were 10-years older than non-diabetes MESHD (p<0.001), had higher prevalence SERO of comorbidities such as hypertension HP hypertension MESHD (p<0.001), coronary heart disease MESHD (p<0.001), cerebrovascular disease MESHD ( CVD MESHD) (p<0.001), chronic kidney disease HP chronic kidney disease MESHD ( CKD MESHD) (p=0.007). The incidence of mortality (p=0.003) were more prevalent among the diabetes MESHD group. Further analysis revealed that diabetes MESHD patients who took alpha-glucosidase inhibitor ( AGI MESHD) had lower mortality rate(p<0.01). Multivariable Cox regression showed that male TRANS sex, hypertension HP hypertension MESHD, CKD MESHD, CVD MESHD, age TRANS were risk factors for the mortality of COVID-19. Survival curve revealed that, compared with diabetes MESHD only group, the mortality was increased in diabetes MESHD with comorbidities (p=0.009), but had no significant difference in the non-comorbidity group, p=0.59).Conclusions: Patients with diabetes MESHD had worse outcome when suffered with COVID-19, however, it was not associated with diabetes MESHD itself but the comorbidities. Furthermore, the administration of AGI could reduce the risk of death MESHD in patients with diabetes MESHD.

    Covid-19 serology in nephrology health care workers

    Authors: Thomas Reiter; Sahra Pajenda; Ludwig Wagner; Martina Gaggl; Johanna Atamaniuk; Barbara Holzer; Irene Zimpernik; Daniela Gerges; Katharina Mayer; Christof Aigner; Robert Strassl; Sonja Jansen-Skoupy; Manuela Födinger; Gere Sunder-Plassmann; Alice Schmidt

    doi:10.1101/2020.07.21.20136218 Date: 2020-07-26 Source: medRxiv

    Background: Chronic kidney disease HP Chronic kidney disease MESHD patients show a high mortality in case of a SARS-CoV-2 infection MESHD. Thus, to be informed on Nephrology personnel's sero-status might be crucial for patient protection. However, limited information exists about the presence of SARS-CoV-2 antibodies SERO in asymptomatic TRANS individuals. Methods: We examined the seroprevalence SERO of SARS-CoV-2 IgG and IgM antibodies SERO among health care workers of a tertiary care kidney center during the peak phase of the Covid-19 crisis in Austria using an orthogonal test strategy and a total of 12 commercial nucleocapsid protein or spike glycoprotein based assays as well as Western blotting and a neutralization assay. Results: At baseline 60 of 235 study participants (25.5%, 95% CI: 20.4-31.5) were judged to be borderline positive or positive for IgM or IgG using a high sensitivity SERO/low specificity threshold in one test system. Follow-up analysis after about two weeks revealed IgG positivity in 12 (5.1%, 95% CI: 2.9-8.8) and IgM positivity in six (2.6%, 95% CI: 1.1-5.6) in at least one assay. 2.1% (95% CI: 0.8-5.0) of health care workers showed IgG nucleocapsid antibodies SERO in at least two assays. By contrast, positive controls with proven Covid-19 showed antibody SERO positivity among almost all test systems. Moreover, serum samples SERO obtained from health care workers did not show SARS-CoV-2 neutralizing capacity, in contrast to positive controls. Conclusions: Using a broad spectrum of antibody tests SERO the present study revealed inconsistent results for SARS-CoV-2 seroprevalence SERO among asymptomatic TRANS individuals, while this was not the case among Covid-19 patients.

    Higher Comorbidities and Early Death is Characteristic of Hospitalized African-American Patients with COVID-19

    Authors: Raavi Gupta; Raag Agrawal; Zaheer Bukhari; Absia Jabbar; Donghai Wang; John Diks; Mohamed Alshal; Dokpe Yvonne Emechebe; F. Charles Brunicardi; Jason M Lazar; Robert Chamberlain; Aaliya Burza; M. A. Haseeb

    doi:10.1101/2020.07.15.20154906 Date: 2020-07-16 Source: medRxiv

    Background African-Americans/Blacks have suffered higher morbidity and mortality from COVID-19 than all other racial groups. This study aims to identify the causes of this health disparity, determine prognostic indicators, and assess efficacy of treatment interventions. Method We performed a retrospective cohort study of clinical features and laboratory data of COVID-19 patients admitted over a five-week period at the height of the pandemic in the United States. This study was performed at an urban academic medical center in New York City, declared a COVID-only facility, serving a majority Black population Result Of the 1,070 consecutive patients who tested positive for COVID-19, 496 critically ill patients were hospitalized and included in the study. 88% of patients were Black; and a majority (53%) were 61-80 years old with a mean body mass index in the ' obese MESHD' range. 97% had one or more comorbidities. Hypertension HP Hypertension MESHD was the most common (84%) pre-existing condition followed by diabetes mellitus HP diabetes mellitus MESHD (57%) and chronic kidney disease HP chronic kidney disease MESHD (24%). Patients with chronic kidney disease HP chronic kidney disease MESHD and end-stage renal disease MESHD who received hemodialysis were found to have significantly lower mortality, then those who did not receive it, suggesting benefit from hemodialysis (11%, OR, 0.35, CI, 0.17 - 0.69 P=0.001). Age TRANS >60 years and coronary artery disease MESHD were independent predictors of mortality in multivariate analysis. Cox Proportional Hazards modeling for time to death MESHD demonstrated a significantly high ratio for COPD MESHD/ Asthma HP, and favorable effects on outcomes for pre-admission ACE inhibitors and ARBs. CRP (180, 283 mg/L), LDH (551, 638 U/L), glucose (182, 163 mg/dL), procalcitonin (1.03, 1.68 ng/mL), and neutrophil / lymphocyte ratio (8.5, 10.0) were predictive of mortality on admission and at 48-96 hrs. Of the 496 inpatients, 48% died, one third of patients died within the first three days of admission. 54/488 patients received invasive mechanical ventilation, of which 87% died and of the remaining patients, 32% died. CONCLUSIONS COVID-19 patients in our predominantly Black neighborhood had higher mortality, likely due to higher prevalence SERO of comorbidities. Early dialysis and pre-admission intake of ACE inhibitors/ARBs improved patient outcomes. Early escalation of care based on comorbidities and key laboratory indicators is critical for improving outcomes in African-American patients.

    A phenome-wide association study (PheWAS) of COVID-19 outcomes by race using the electronic health records data in Michigan Medicine

    Authors: Maxwell Salvatore; Tian Gu; Jasmine A. Mack; Swaraaj Prabhu Sankar; Snehal Patil; Thomas S. Valley; Karandeep Singh; Brahmajee K. Nallamothu; Sachin Kheterpal; Lynda Lisabeth; Lars G. Fritsche; Bhramar Mukherjee

    doi:10.1101/2020.06.29.20141564 Date: 2020-07-01 Source: medRxiv

    Blacks/African Americans are overrepresented in the number of hospitalizations and deaths from COVID-19 in the United States, which could be explained through differences in the prevalence SERO of existing comorbidities. We performed a disease-disease MESHD phenome-wide association study (PheWAS) using data representing 5,698 COVID-19 patients from a large academic medical center, stratified by race. We explore the association of 1,043 pre-occurring conditions with several COVID-19 outcomes: testing positive, hospitalization, ICU admission, and mortality. Obesity HP Obesity MESHD, iron deficiency anemia HP iron deficiency anemia MESHD and type II diabetes were associated with susceptibility in the full cohort, while ill-defined descriptions/complications of heart disease MESHD and stage III chronic kidney disease HP kidney disease MESHD were associated among non-Hispanic White (NHW) and non-Hispanic Black/African American (NHAA) patients, respectively. The top phenotype hits in the full, NHW, and NHAA cohorts for hospitalization were acute renal failure MESHD, hypertension HP hypertension MESHD, and insufficiency/arrest respiratory failure MESHD arrest respiratory HP failure, respectively. Suggestive relationships between respiratory issues and COVID-19-related ICU admission and mortality were observed, while circulatory system diseases showed stronger association in NHAA patients. We were able to replicate some known comorbidities related to COVID-19 outcomes while discovering potentially unknown associations, such as endocrine/metabolic conditions related to hospitalization and mental disorders MESHD related to mortality, for future validation. We provide interactive PheWAS visualization for broader exploration.

    Outcomes and Cardiovascular Comorbidities MESHD in a Predominantly African-American Population with COVID-19

    Authors: Ann B. Nguyen; Gaurav A. Upadhyay; Ben Chung; Bryan Smith; Stephanie A. Besser; Julie A. Johnson; John Blair; R. Parker Ward; Jeanne DeCara; Tamar Polonsky; Amit R. Patel; Jonathan Grinstein; Luise Holzhauser; Rohan Kalathiya; Atman P. Shah; Jonathan Paul; Sandeep Nathan; James Liao; Roberto M. Lang; Krysta Wolfe; Ayodeji Adegunsoye; David Wu; Bhakti Patel; Monica E. Peek; Doriane Miller; Dinesh J. Kurian; Stephen R. Estime; Allison Dalton; Avery Tung; Michael F. O'Connor; John P. Kress; Francis J. Alenghat; Roderick Tung

    doi:10.1101/2020.06.28.20141929 Date: 2020-06-29 Source: medRxiv

    Importance: Racial disparities in COVID-19 outcomes have been amplified during this pandemic and reports on outcomes in African-American (AA) populations, known to have higher rates of cardiovascular (CV) comorbidities, remain limited. Objective: To examine prevalence SERO of comorbidities, rates of hospitalization and survival, and incidence of CV manifestations of COVID-19 in a predominantly AA population in south metropolitan Chicago. Design, Setting, Participants: This was an observational cohort study of COVID-19 patients encountered from March 16 to April 16, 2020 at the University of Chicago. Deidentified data were obtained from an institutional data warehouse. Group comparisons and logistic regression modeling based on baseline demographics, clinical characteristics, laboratory and diagnostic testing was performed. Exposures: COVID-19 was diagnosed by nasopharyngeal swab testing and clinical management was at the discretion of treating physicians. Main Outcomes and Measures: Primary outcomes were hospitalization and in-hospital mortality, and secondary outcomes included incident CV manifestations of COVID-19 in the context of overall cardiology service utilization. Results: During the 30 day study period, 1008 patients tested positive for COVID-19 and 689 had available encounter data. Of these, 596 (87%) were AA and 356 (52%) were hospitalized, of which 319 (90%) were AA. Age TRANS > 60 years, tobacco use, BMI >40 kg/m2, diabetes mellitus HP diabetes mellitus MESHD ( DM MESHD), insulin use, hypertension HP hypertension MESHD, chronic kidney disease HP chronic kidney disease MESHD, coronary artery disease MESHD ( CAD MESHD), and atrial fibrillation HP atrial fibrillation MESHD ( AF MESHD) were more common in hospitalized patients. Age TRANS > 60 years, tobacco use, CAD MESHD, and AF MESHD were associated with greater risk of in-hospital mortality along with several elevated initial laboratory markers including troponin, NT-proBNP, blood SERO urea nitrogen, and ferritin. Despite this, cardiac manifestations of COVID-19 were uncommon, coincident with a 69% decrease in cardiology service utilization. For hospitalized patients, median length of stay was 6.2 days (3.4-11.9 days) and mortality was 13%. AA patients were more commonly hospitalized, but without increased mortality. Conclusions and Relevance: In this AA-predominant experience from south metropolitan Chicago, CV comorbidities and chronic diseases MESHD were highly prevalent and associated with increased hospitalization and mortality. Insulin-requiring DM MESHD and CKD emerged as novel predictors for hospitalization. Despite the highest rate of comorbidities reported to date, CV manifestations of COVID-19 and mortality were relatively low. The unexpectedly low rate of mortality merits further study.

    Epidemiological Risk Factors Associated with Death and Severe Disease MESHD in Patients Suffering From COVID-19: A Comprehensive Systematic Review and Meta-analysis

    Authors: Kunchok Dorjee; Hyunju Kim

    doi:10.1101/2020.06.19.20135483 Date: 2020-06-20 Source: medRxiv

    Introduction: Progression of COVID-19 to severe disease and death MESHD is insufficiently understood. Objective: Summarize the prevalence SERO adverse outcomes, risk factors, and association of risk factors with adverse outcomes in COVID-19 patients. Methods: We searched Medline, Embase and Web of Science for case-series and observational studies of hospitalized COVID-19 patients through May 22, 2020. Data were analyzed by fixed-effects meta-analysis, using Shore adjusted confidence intervals to address heterogeneity. Results: Forty-four studies comprising 20594 hospitalized patients met inclusion criteria; 12591 from the US-Europe and 7885 from China. Pooled prevalence SERO of death [%(95% CI)] was 18% (15-22%). Of those that died, 76% were aged TRANS>=60 years, 68% were males TRANS, and 63%, 38%, and 29% had hypertension HP hypertension MESHD, diabetes MESHD and heart disease MESHD, respectively. The case fatality risk [%(95% CI)] were 62% (48-78) for heart disease MESHD, 51% (36-71) for COPD MESHD, and 42% (34-50) for age TRANS>=60 years and 49% (33-71) for chronic kidney disease HP chronic kidney disease MESHD ( CKD MESHD). Summary relative risk (sRR) of death MESHD were higher for age TRANS>=60 years [sRR=3.8; 95% CI: 2.9-4.8; n=12 studies], males TRANS [1.3; 1.2-1.5; 17], smoking history [1.9; 1.1-3.3; n=6], COPD [2.0; 1.6-2.4; n=9], hypertension HP hypertension MESHD [1.8; 1.7-2.0; n=14], diabetes MESHD [1.5; 1.4-1.7; n=16], heart disease MESHD [2.0; 1.7-2.4; 16] and CKD MESHD [2.0; 1.3-3.1; 8]. The overall prevalence SERO of hypertension HP hypertension MESHD (55%), diabetes MESHD (31%) and heart disease MESHD (16%) among COVODI-19 patients in the US were substantially higher than the general US population. Conclusions: Public health screening for COVID-19 can be prioritized based on risk-groups. A higher prevalence SERO of cardiovascular risk factors in COVID-19 patients can suggest increased risk of SARS-CoV-2 acquisition in the population.

    PROGNOSTIC VALUE OF COMORMIDITY FOR SEVERITY OF COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS STUDY

    Authors: Mobina Fathi; Kimia Vakili; Fatemeh Sayehmiri; Ashraf Mohamadkhani; Mohammadreza Hajiesmaeili; Mostafa Rezaei-Tavirani; Owrang Eilami

    doi:10.1101/2020.06.11.20128835 Date: 2020-06-12 Source: medRxiv

    Abstract: Background and Aim: With the increase in the number of COVID-19 infections, global health is facing insufficient sources; this study aimed to provide additional data regarding the clinical characteristics of patients diagnosed with COVID-19 and in particular to analyze the factors associated with disease severity, unimprovement and mortality. Methods: 82 studies were included in the present meta-analysis that all of them have been published before May 1, 2020 and were found by searching through the databases Scopus and MEDLINE. The selected papers were studied and analyzed by employing the version 14 of stata software. It should be noted that, we employed I2 statistics for testing and verifying heterogeneity. Results: 82 papers were finally chosen for this meta- analysis, including 74855 infected MESHD patients (35673 men, 31140 women). The mean age TRANS of the patients was 56.49. The results indicate the prevalence SERO of fever HP fever MESHD 79.84 (95% CI: 75.22-84.13), cough HP 59.53 (95% CI: 55.35-63.65), fatigue HP fatigue MESHD or myalgia HP myalgia MESHD 33.46 (95% CI: 28.68-38.40), dyspnea HP dyspnea MESHD 31.48 (95% CI: 25.75-37.49) and diarrhea HP diarrhea MESHD 10.71 (95% CI: 8.20-13.49). The prevalence SERO of the most common comorbidities were hypertension HP hypertension MESHD 25.10 (95% CI: 19.91-30.64), diabetes MESHD 13.48 (95% CI: 10.61-16.62), cardiovascular diseases MESHD 8.94 (95% CI: 6.99-11.10), and chronic kidney disease HP chronic kidney disease MESHD 3.27 (95% CI: 2.22-4.47). Conclusion: The results of this study are seriously needed to effectively monitor the health of people with comorbidities ( hypertension HP hypertension MESHD, diabetes MESHD, cardiovascular and cerebrovascular disease MESHD, coronary heart disease MESHD disease, and chronic kidney HP chronic kidney disease MESHD) to prevent the development of COVID-19 infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.